Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and ...

Here, we used deep full-length single-cell RNA-sequencing to distinguish post-mitotic cone and rod developmental states and cone-specific features that contribute to retinoblastomagenesis. The ...

Ongoing fundamental research on cancer cells could be used to create new drugs and therapies that fight the spread of cancer ...

This communication between infected neurons and the immune system happens through molecules called neuropeptides, which ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on FATE stock, giving a Buy rating yesterday. Daina ...

Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...

FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The company's innovative ...